**[87] IMMUNARRAY: ICHIP®-BASED AUTOIMMUNE DISEASE MANAGEMENT**

**Pennina Safer1, Donna Edmonds1, D. Scott Batty Jr.1, 1 Immunarray**

**Investment Rational**
ImmunArray develops and markets novel iCHIP®-based blood tests to support diagnosis and management of immune-mediated and neurodegenerative diseases. ImmunArray has also licensed a portfolio of biomarkers for identification and management of Brain Injury patients. The company, with offices in Rehovot, Israel and Richmond, VA, is managed by seasoned executives including Chairman & CEO, Donna Edmonds, a veteran international industry leader.

**Business Strategy**In October 2015 ImmunArray launched its SLE-*key*®RuleOut testing service for the RuleOut of a diagnosis of systemic lupus erythematosus (SLE) through Veracis, its wholly owned CLIA lab (Richmond VA). A Disease Activity Monitoring test based on the SLE-key® platform is planned for late 2016. Initial payer coverage supports the company’s expectations of EBIDTA breakeven by end 2017.

**Core Technology**The proprietary iCHIP® microarray/analytics platform profiles patient autoantibody repertoires for early identification and effective monitoring of patients with complex autoimmune diseases.

For Brain Injury franchise development, the company is evaluating samples from its 500-patient prospective clinical study (HeadSMART) on a proprietary portfolio of more than 20 biomarkers to develop products for diagnosis and management of acute and chronic brain injury.

**Product Profile/Pipeline**SLE-key®RuleOut based on the iCHIP® platform, was launched to assist rheumatologists to rule-out a diagnosis of SLE with an unmatched combination of sensitivity (94%), specificity (75%), and NPV (93%). Prior to commercial launch, almost 200 tests from 16 rheumatology practices were processed under a Research Use Only program. All practices were converted to commercial customers and additional customers are being added weekly.

**What's Next?**
ImmunArray’s proprietary customizable iCHIP® platform enables detection, monitoring and management of immune-mediated and neurodegenerative diseases. The company will use the platform alone and in collaboration with pharma and diagnostic strategic partners to develop products for traumatic brain injury (>$1B), rheumatoid arthritis (>$1B), Crohn’s disease (>$500M), immuno-oncology (>$300M) and multiple sclerosis (>$300M).